Scarica l'app Stockscreener
3.58
2.47%
-0.07
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché EDIT Giù?
Forum
Previsione
Editas Medicine Inc Borsa (EDIT) Ultime notizie
Editas Medicine, Inc.(NasdaqGS:EDIT) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Editas Medicine, Inc.(NasdaqGS: EDIT) added to Russell 2500 Growth Benchmark - marketscreener.com
Editas Medicine, Inc.(NasdaqGS: EDIT) added to Russell 2000 Growth Benchmark - marketscreener.com
Editas Medicine, Inc.(NasdaqGS: EDIT) added to Russell 3000E Growth Benchmark - marketscreener.com
Editas Medicine, Inc.(NasdaqGS: EDIT) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Price to sales forward of Editas Medicine, Inc. – NASDAQ:EDIT - TradingView
Price to sales forward of Editas Medicine, Inc. – LSE:0IFK - TradingView
Price to earnings forward of Editas Medicine, Inc. – NASDAQ:EDIT - TradingView
Enterprise value to EBITDA forward of Editas Medicine, Inc. – NASDAQ:EDIT - TradingView
Price to earnings forward of Editas Medicine, Inc. – LSE:0IFK - TradingView
Enterprise value to revenue forward of Editas Medicine, Inc. – NASDAQ:EDIT - TradingView
Price to book forward of Editas Medicine, Inc. – NASDAQ:EDIT - TradingView
Editas Medicine, Inc. Actuals & Estimates (NASDAQ:EDIT) - TradingView
Enterprise value to EBITDA forward of Editas Medicine, Inc. – LSE:0IFK - TradingView
Editas Medicine, Inc. Actuals & Estimates (LSE:0IFK) - TradingView
EDIT Forecast — Price Target — Prediction for 2027 - TradingView
Editas Medicine, Inc. Actuals & Estimates (FWB:8EM) - TradingView
Editas Medicine Inc (EDIT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Editas Medicine, Inc. Actuals & Estimates (BOATS:EDIT) - TradingView
8EM Forecast — Price Target — Prediction for 2027 - TradingView
Editas Medicine Inc (EDIT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Editas Medicine | 4: Statement of changes in beneficial ownership of securities-Director Hirsch Andrew - Moomoo
Editas Medicine | 4: Statement of changes in beneficial ownership of securities-Director Scadden David - Moomoo
Editas Medicine Inc (EDIT) Institutional Confidence - TradingKey
Form 4 Editas Medicine For: 22 June By Investing.com - Investing.com South Africa
[Form 4] Editas Medicine, Inc. Insider Trading Activity - Stock Titan
Editas Medicine | 4: Statement of changes in beneficial ownership of securities-Director Connaughton Bernadette - Moomoo
Editas Medicine (NASDAQ: EDIT) director granted 51,700 stock options at $2.55 - Stock Titan
Editas Medicine | 4: Statement of changes in beneficial ownership of securities-Director Hopfield Jessica - Moomoo
Editas Medicine (EDIT) director Andrew Hirsch awarded 51,700 stock options - Stock Titan
Editas Medicine (EDIT) director awarded 51,700 stock options at $2.55 strike - Stock Titan
Editas Medicine (EDIT) director granted 51,700 stock options at $2.55 strike - Stock Titan
Editas Medicine elects two directors and ratifies auditor at annual meeting - Investing.com Canada
Editas Medicine elects two directors and ratifies auditor at annual meeting By Investing.com - Investing.com South Africa
Editas Medicine (NASDAQ: EDIT) stockholders elect directors and ratify PwC at 2026 meeting - Stock Titan
Editas Medicine Inc (EDIT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Editas Medicine Inc (EDIT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Editas Medicine Inc (EDIT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Editas Medicine Inc (EDIT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Editas Medicine Inc (EDIT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Editas Medicine Inc (EDIT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Editas Medicine Inc Annual Shareholders Meeting Transcript - GuruFocus
Editas Medicine Shares Slide 9.36%: Key Support Levels in FocusJelly Roll Trade - dars.gov.et
Editas Medicine CEO Gilmore O’Neill sells $41,542 in stock By Investing.com - Investing.com India
RA CAPITAL MANAGEMENT, L.P. Acquires Significant Stake in Editas Medicine Inc - GuruFocus
COMMODORE CAPITAL LP Acquires Significant Stake in Editas Medici - GuruFocus
Editas Medicine CFO Amy Parison sells $1,253 in stock By Investing.com - Investing.com South Africa
Editas Medicine CEO Gilmore O’Neill sells $41,542 in stock - Investing.com
1.95%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):